UA70315C2 - Pharmaceutical composition comprising metformin anpharmaceutical composition comprising metformin and fibrate useful for formulations intended for lowd fibrate useful for formulations intended for lowering hyperglycemia ering hyperglycemia - Google Patents

Pharmaceutical composition comprising metformin anpharmaceutical composition comprising metformin and fibrate useful for formulations intended for lowd fibrate useful for formulations intended for lowering hyperglycemia ering hyperglycemia Download PDF

Info

Publication number: UA70315C2
Authority: UA; Ukraine
Prior art keywords: metformin; fibrate; hyperglycemia; useful; pharmaceutical composition
Prior art date: 1998-02-12

Application number

UA2000095172A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Merck Patent Gmbh Merck Patent

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-12

Filing date

1999-01-30

Publication date

2004-10-15

1999-01-30 Application filed by Merck Patent Gmbh Merck Patent filed Critical Merck Patent Gmbh Merck Patent

2004-10-15 Publication of UA70315C2 publication Critical patent/UA70315C2/uk

Links

229960003105 metformin Drugs 0.000 title claims abstract description 45
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract description 42
229940125753 fibrate Drugs 0.000 title claims abstract description 23
239000000203 mixture Substances 0.000 title claims abstract description 20
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
201000001421 hyperglycemia Diseases 0.000 title claims description 10
238000009472 formulation Methods 0.000 title 2
239000013543 active substance Substances 0.000 claims abstract description 16
150000003839 salts Chemical class 0.000 claims abstract description 16
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
229960000516 bezafibrate Drugs 0.000 claims description 20
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 claims description 20
229960002297 fenofibrate Drugs 0.000 claims description 18
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 18
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 13
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
FBZWYFBNIGSUPS-UHFFFAOYSA-N (2-chlorophenyl) ethaneperoxoate Chemical compound CC(=O)OOC1=CC=CC=C1Cl FBZWYFBNIGSUPS-UHFFFAOYSA-N 0.000 claims description 4
208000032928 Dyslipidaemia Diseases 0.000 claims description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
229950005627 embonate Drugs 0.000 claims description 4
238000012876 topography Methods 0.000 claims 1
206010012601 diabetes mellitus Diseases 0.000 abstract description 5
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 4
102000004877 Insulin Human genes 0.000 abstract description 2
108090001061 Insulin Proteins 0.000 abstract description 2
229940125396 insulin Drugs 0.000 abstract description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
229960001214 clofibrate Drugs 0.000 description 7
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 7
-1 embonate Chemical compound 0.000 description 7
238000000034 method Methods 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 6
235000012000 cholesterol Nutrition 0.000 description 6
239000000243 solution Substances 0.000 description 6
241000700159 Rattus Species 0.000 description 5
230000000694 effects Effects 0.000 description 5
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
239000003524 antilipemic agent Substances 0.000 description 4
239000000945 filler Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
229960001052 streptozocin Drugs 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000003472 antidiabetic agent Substances 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000000975 dye Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
239000008103 glucose Substances 0.000 description 3
229940126904 hypoglycaemic agent Drugs 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000000375 suspending agent Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
239000003826 tablet Substances 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
229920002907 Guar gum Polymers 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
229940100389 Sulfonylurea Drugs 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 description 2
230000002058 anti-hyperglycaemic effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
201000005577 familial hyperlipidemia Diseases 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000000227 grinding Methods 0.000 description 2
239000000665 guar gum Substances 0.000 description 2
235000010417 guar gum Nutrition 0.000 description 2
229960002154 guar gum Drugs 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
230000002218 hypoglycaemic effect Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000003094 microcapsule Substances 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
238000002156 mixing Methods 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000000843 powder Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
235000010413 sodium alginate Nutrition 0.000 description 2
239000000661 sodium alginate Substances 0.000 description 2
229940005550 sodium alginate Drugs 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
239000002904 solvent Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
229940033134 talc Drugs 0.000 description 2
230000002792 vascular Effects 0.000 description 2
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
HZNQSWJZTWOTKM-UHFFFAOYSA-N 2,3,4-trimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C(OC)=C1OC HZNQSWJZTWOTKM-UHFFFAOYSA-N 0.000 description 1
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-M 5-oxo-L-prolinate Chemical compound [O-]C(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-M 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
244000223760 Cinnamomum zeylanicum Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
102000007330 LDL Lipoproteins Human genes 0.000 description 1
108010007622 LDL Lipoproteins Proteins 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
239000005913 Maltodextrin Substances 0.000 description 1
235000006679 Mentha X verticillata Nutrition 0.000 description 1
235000002899 Mentha suaveolens Nutrition 0.000 description 1
235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229940116229 borneol Drugs 0.000 description 1
CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
229940078456 calcium stearate Drugs 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229960001777 castor oil Drugs 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
229960002242 chlorocresol Drugs 0.000 description 1
235000017803 cinnamon Nutrition 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000008094 contradictory effect Effects 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
229940013361 cresol Drugs 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
NZNMSOFKMUBTKW-UHFFFAOYSA-M cyclohexanecarboxylate Chemical compound [O-]C(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-M 0.000 description 1
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
229940075933 dithionate Drugs 0.000 description 1
DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000035622 drinking Effects 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
229960004667 ethyl cellulose Drugs 0.000 description 1
238000011049 filling Methods 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
229940046813 glyceryl palmitostearate Drugs 0.000 description 1
HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
230000000055 hyoplipidemic effect Effects 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
229940059904 light mineral oil Drugs 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
229940035034 maltodextrin Drugs 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
235000019691 monocalcium phosphate Nutrition 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229960005222 phenazone Drugs 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
235000007686 potassium Nutrition 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
229940071139 pyrrolidone carboxylate Drugs 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
ZLVSYODPTJZFMK-UHFFFAOYSA-M sodium 4-hydroxybenzoate Chemical compound [Na+].OC1=CC=C(C([O-])=O)C=C1 ZLVSYODPTJZFMK-UHFFFAOYSA-M 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
229960004274 stearic acid Drugs 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
WFKQDJGWWJDZGR-UHFFFAOYSA-K trisodium 2-hydroxyacetate Chemical compound C(CO)(=O)[O-].[Na+].[Na+].[Na+].C(CO)(=O)[O-].C(CO)(=O)[O-] WFKQDJGWWJDZGR-UHFFFAOYSA-K 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940057977 zinc stearate Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

UA2000095172A 1998-02-12 1999-01-30 Pharmaceutical composition comprising metformin anpharmaceutical composition comprising metformin and fibrate useful for formulations intended for lowd fibrate useful for formulations intended for lowering hyperglycemia ering hyperglycemia UA70315C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9801709A FR2774591B1 (fr)	1998-02-12	1998-02-12	Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
PCT/EP1999/000614 WO1999040904A2 (en)	1998-02-12	1999-01-30	Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia

Publications (1)

Publication Number	Publication Date
UA70315C2 true UA70315C2 (en)	2004-10-15

Family

ID=9522912

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2000095172A UA70315C2 (en)	1998-02-12	1999-01-30	Pharmaceutical composition comprising metformin anpharmaceutical composition comprising metformin and fibrate useful for formulations intended for lowd fibrate useful for formulations intended for lowering hyperglycemia ering hyperglycemia

Country Status (27)

Country	Link
US (1)	US6372790B1 (es)
EP (1)	EP1054665B1 (es)
JP (1)	JP4767411B2 (es)
KR (1)	KR100567608B1 (es)
CN (1)	CN1151785C (es)
AR (1)	AR018286A1 (es)
AT (1)	ATE204754T1 (es)
AU (1)	AU746821B2 (es)
BR (1)	BRPI9907866B8 (es)
CA (1)	CA2320039C (es)
CZ (1)	CZ290101B6 (es)
DE (1)	DE69900249T2 (es)
DK (1)	DK1054665T3 (es)
ES (1)	ES2162517T3 (es)
FR (1)	FR2774591B1 (es)
HU (1)	HU224619B1 (es)
ID (1)	ID26254A (es)
MY (1)	MY118164A (es)
NO (1)	NO328314B1 (es)
PL (1)	PL196874B1 (es)
PT (1)	PT1054665E (es)
RU (1)	RU2207850C2 (es)
SK (1)	SK283212B6 (es)
TW (1)	TW518222B (es)
UA (1)	UA70315C2 (es)
WO (1)	WO1999040904A2 (es)
ZA (1)	ZA991077B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69822505T2 (de) *	1997-12-08	2005-01-20	Bristol-Myers Squibb Co.	Neue metformin-salze und verfahren
US6982281B1 (en)	2000-11-17	2006-01-03	Lipocine Inc	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2796551B1 (fr) *	1999-07-23	2003-07-25	Lipha	Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
FR2796940B1 (fr) *	1999-07-26	2005-04-08	Lipha	Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6586438B2 (en)	1999-11-03	2003-07-01	Bristol-Myers Squibb Co.	Antidiabetic formulation and method
AU2001236457A1 (en) *	2000-01-13	2001-07-24	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6531158B1 (en) *	2000-08-09	2003-03-11	Impax Laboratories, Inc.	Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
JP4829411B2 (ja) *	2001-02-23	2011-12-07	キッセイ薬品工業株式会社	Ｃ型慢性肝炎治療剤
GB0119480D0 (en)	2001-08-09	2001-10-03	Jagotec Ag	Novel compositions
EP1515701B1 (en)	2002-06-17	2014-09-17	Inventia Healthcare Private Limited	Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
EP1424070A1 (en) *	2002-11-28	2004-06-02	Fournier Laboratories Ireland Limited	Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides
BR0215979A (pt)	2002-12-13	2005-11-01	Jagotec Ag	Formulação de espironolactona nanoparticulada tópica, uso de nanossuspensões de espironolactona, sistema de rede cristalina, e, processo para a preparação de uma formulação de espironolactona nanoparticulada tópica
KR20050097537A (ko) *	2003-02-07	2005-10-07	아지노모토 가부시키가이샤	당뇨병 치료제
FR2851734B1 (fr) *	2003-02-28	2006-06-09	Galenix Innovations	Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
FR2858556B1 (fr) *	2003-08-06	2006-03-10	Galenix Innovations	Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
RU2241449C1 (ru) *	2003-09-25	2004-12-10	Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин"	Фармацевтическая композиция для лечения диабета (варианты)
US8062664B2 (en) *	2003-11-12	2011-11-22	Abbott Laboratories	Process for preparing formulations of lipid-regulating drugs
SG149814A1 (en) *	2003-12-19	2009-02-27	Omega Bio Pharma Ip3 Ltd	Compositions and methods for treating diabetes
EP1559419A1 (en) *	2004-01-23	2005-08-03	Fournier Laboratories Ireland Limited	Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
JP4901218B2 (ja) *	2004-02-09	2012-03-21	あすか製薬株式会社	併用医薬
EP1591114A1 (en) *	2004-03-12	2005-11-02	Fournier Laboratories Ireland Limited	Use of metformin and orlistat for the treatment or prevention of obesity
US20060286182A1 (en) *	2005-06-21	2006-12-21	Abeille Pharmaceuticals, Inc.	Synergistic cinnamon combinations and methods for enhancing insulin activity
GB0602639D0 (en) *	2006-02-09	2006-03-22	Novartis Ag	Organic compounds
CA2657394A1 (en)	2006-08-04	2008-02-07	Aska Pharmaceutical Co., Ltd.	Preparation containing fibrate agent and process for producing the same
CN101342164B (zh) *	2007-08-21	2011-04-20	阜新市仙鹤制药有限责任公司	苯扎贝特控释制剂及其制备方法
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
US9339458B2 (en) *	2009-02-18	2016-05-17	Itf Research Pharma, S.L.U.	Use of vaginal insulin sensitizing agents
ES2344183B1 (es) *	2009-02-18	2011-06-10	Italfarmaco, S.A.	Uso de agentes sensibilizantes a insulina por via vaginal.
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
JP2012171911A (ja)	2011-02-22	2012-09-10	Kao Corp	Ｐｐａｒ活性化剤
US9382187B2 (en) *	2012-07-10	2016-07-05	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
WO2014011814A1 (en) *	2012-07-10	2014-01-16	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
US8765811B2 (en) *	2012-07-10	2014-07-01	Thetis Pharmaceuticals Llc	Tri-salt form of metformin
US9505709B2 (en)	2014-05-05	2016-11-29	Thetis Pharmaceuticals Llc	Compositions and methods relating to ionic salts of peptides
US10166246B2 (en)	2014-05-27	2019-01-01	City Of Hope	TGR5 agonist complexes for treating diabetes and cancer
BR112016029476A2 (pt)	2014-06-18	2017-08-22	Thetis Pharmaceuticals Llc	complexos de aminoácido mineral de agentes ativos
US9242008B2 (en)	2014-06-18	2016-01-26	Thetis Pharmaceuticals Llc	Mineral amino-acid complexes of fatty acids
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en)	2014-08-28	2017-08-31	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016205423A2 (en)	2015-06-15	2016-12-22	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
FR3050112B1 (fr) *	2016-04-15	2020-09-04	Soc Civ Immobiliere Gecinq	Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
DK3454907T3 (da)	2016-06-03	2020-10-19	Thetis Pharmaceuticals Llc	Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation
US10344002B2 (en)	2016-09-26	2019-07-09	Nusirt Sciences, Inc.	Compositions and methods for treating metabolic disorders
FR3056908B1 (fr) *	2016-09-30	2019-04-19	Nashpharm	Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
CA3078723A1 (en)	2016-11-28	2018-05-31	Nachiappan Chidambaram	Oral testosterone undecanoate therapy
US12150945B2 (en)	2018-07-20	2024-11-26	Lipocine Inc.	Liver disease
GB2599950A (en) *	2020-10-16	2022-04-20	Zentiva Ks	Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
US20250127900A1 (en) *	2021-12-22	2025-04-24	Mankind Pharma Ltd.	Stable pharmaceutical compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2264525B1 (es) *	1974-03-22	1977-11-04	Expl Marques Brevets Et
US4080472A (en)	1974-03-22	1978-03-21	Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S.	Metformin 2-(p-chlorophenoxy)-2-methylpropionate
DE3729209A1 (de) *	1987-09-01	1989-03-09	Boehringer Mannheim Gmbh	Verwendung von bezafibrat zur behandlung von diabetes
NZ240214A (en) *	1990-10-16	1993-02-25	Takeda Chemical Industries Ltd	Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
JP3852621B2 (ja) *	1992-01-21	2006-12-06	あすか製薬株式会社	血管内皮細胞機能改善剤
WO1998005331A2 (en) *	1996-08-02	1998-02-12	Ligand Pharmaceuticals Incorporated	Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

1998
- 1998-02-12 FR FR9801709A patent/FR2774591B1/fr not_active Expired - Lifetime
1999
- 1999-01-30 ES ES99910169T patent/ES2162517T3/es not_active Expired - Lifetime
- 1999-01-30 PT PT81108560T patent/PT1054665E/pt unknown
- 1999-01-30 UA UA2000095172A patent/UA70315C2/uk unknown
- 1999-01-30 RU RU2000123567/14A patent/RU2207850C2/ru active
- 1999-01-30 BR BR9907866A patent/BRPI9907866B8/pt not_active IP Right Cessation
- 1999-01-30 ID IDW20001765A patent/ID26254A/id unknown
- 1999-01-30 CA CA002320039A patent/CA2320039C/en not_active Expired - Lifetime
- 1999-01-30 EP EP99910169A patent/EP1054665B1/en not_active Expired - Lifetime
- 1999-01-30 WO PCT/EP1999/000614 patent/WO1999040904A2/en not_active Ceased
- 1999-01-30 AT AT99910169T patent/ATE204754T1/de active
- 1999-01-30 US US09/601,618 patent/US6372790B1/en not_active Expired - Lifetime
- 1999-01-30 JP JP2000531156A patent/JP4767411B2/ja not_active Expired - Lifetime
- 1999-01-30 DE DE69900249T patent/DE69900249T2/de not_active Expired - Lifetime
- 1999-01-30 HU HU0100801A patent/HU224619B1/hu active IP Right Grant
- 1999-01-30 CN CNB998029041A patent/CN1151785C/zh not_active Expired - Lifetime
- 1999-01-30 CZ CZ20002828A patent/CZ290101B6/cs not_active IP Right Cessation
- 1999-01-30 KR KR1020007008836A patent/KR100567608B1/ko not_active Expired - Lifetime
- 1999-01-30 DK DK99910169T patent/DK1054665T3/da active
- 1999-01-30 SK SK1156-2000A patent/SK283212B6/sk not_active IP Right Cessation
- 1999-01-30 PL PL342665A patent/PL196874B1/pl unknown
- 1999-01-30 AU AU29233/99A patent/AU746821B2/en not_active Expired
- 1999-02-09 MY MYPI99000445A patent/MY118164A/en unknown
- 1999-02-10 ZA ZA9901077A patent/ZA991077B/xx unknown
- 1999-02-10 TW TW088102063A patent/TW518222B/zh not_active IP Right Cessation
- 1999-02-12 AR ARP990100598A patent/AR018286A1/es active IP Right Grant
2000
- 2000-08-11 NO NO20004056A patent/NO328314B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CZ20002828A3 (cs)	2000-11-15
KR100567608B1 (ko)	2006-04-04
NO20004056L (no)	2000-08-11
FR2774591B1 (fr)	2000-05-05
HU224619B1 (hu)	2005-11-28
EP1054665B1 (en)	2001-08-29
DK1054665T3 (da)	2001-12-27
WO1999040904A3 (en)	1999-09-30
NO328314B1 (no)	2010-01-25
KR20010040925A (ko)	2001-05-15
CN1151785C (zh)	2004-06-02
DE69900249D1 (de)	2001-10-04
ES2162517T3 (es)	2001-12-16
MY118164A (en)	2004-09-30
ZA991077B (en)	1999-08-11
BR9907866A (pt)	2000-10-31
HUP0100801A3 (en)	2001-12-28
CZ290101B6 (cs)	2002-05-15
AU2923399A (en)	1999-08-30
AU746821B2 (en)	2002-05-02
WO1999040904A2 (en)	1999-08-19
HK1034913A1 (en)	2001-11-09
ATE204754T1 (de)	2001-09-15
NO20004056D0 (no)	2000-08-11
BRPI9907866B8 (pt)	2021-05-25
PL342665A1 (en)	2001-07-02
SK11562000A3 (sk)	2000-12-11
RU2207850C2 (ru)	2003-07-10
AR018286A1 (es)	2001-11-14
JP4767411B2 (ja)	2011-09-07
CA2320039C (en)	2008-07-22
PT1054665E (pt)	2002-02-28
CA2320039A1 (en)	1999-08-19
SK283212B6 (sk)	2003-03-04
BRPI9907866B1 (pt)	2017-08-15
CN1290160A (zh)	2001-04-04
PL196874B1 (pl)	2008-02-29
FR2774591A1 (fr)	1999-08-13
EP1054665A2 (en)	2000-11-29
HUP0100801A2 (hu)	2001-08-28
TW518222B (en)	2003-01-21
DE69900249T2 (de)	2002-06-13
ID26254A (id)	2000-12-07
US6372790B1 (en)	2002-04-16
JP2002502869A (ja)	2002-01-29

Publication	Publication Date	Title
UA70315C2 (en)	2004-10-15	Pharmaceutical composition comprising metformin anpharmaceutical composition comprising metformin and fibrate useful for formulations intended for lowd fibrate useful for formulations intended for lowering hyperglycemia ering hyperglycemia
US5614560A (en)	1997-03-25	Method of preventing NMDA receptor-mediated neuronal damage
US5334618A (en)	1994-08-02	Method of preventing NMDA receptor-mediated neuronal damage
KR100573333B1 (ko)	2006-04-24	지질 수준 저하를 위한 시부트라민 동족체의 용도
WO1994005275A9 (en)	1994-04-28	Method of preventing nmda receptor-mediated neuronal damage
KR20050113163A (ko)	2005-12-01	모다피닐의 제약 제제
CN1273531A (zh)	2000-11-15	用铬/生物素治疗ⅱ型糖尿病
NZ501966A (en)	2001-12-21	Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders
US20080161604A1 (en)	2008-07-03	Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy
US8952059B2 (en)	2015-02-10	Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes
JPH0251885B2 (es)	1990-11-08
ES2425045T3 (es)	2013-10-11	Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa
MXPA06014907A (es)	2007-03-21	Uso de acetil l-carnitina para preparacion de medicina para tratamiento de dolor neuropatico en pacientes diabeticos.
JP5685362B2 (ja)	2015-03-18	有痛性末梢糖尿病性神経障害の予防のためのアセチルｌ−カルニチン
AU705888B2 (en)	1999-06-03	Method of preventing NMDA receptor-mediated neuronal damage
MXPA00007739A (es)	2001-11-21	Composicion farmaceutica que comprende una combinacion de metformina y fibrato, y su uso para la preparacion de medicinas pensadas para reducir la hiperglicemia
MXPA96002793A (es)	1998-01-01	Uso de sertralina para tratar pacientes despues de un infarto de miocardio
WO2003092726A1 (en)	2003-11-13	Combination of insulin and a thiazolidinedione derivative, and use thereof for treating diabetes